Lipid-lowering effects of colesevelam HCl in combination with ezetimibe

References

• LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease [A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association]. Circulation 1990;81:1721–33
   Google Scholar
• Jacobson TA. Clinical context: current concepts of coronary heart disease management. Am J Med 2001;110(Suppl 6A): 3S–11S
   Google Scholar
• Stein EA. Identification and treatment of individuals at high risk of coronary heart disease. Am J Med 2002;112(Suppl 8A): 3S–9
   Google Scholar
• NCEP-ATP. NCEP-ATP III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert panel report. Bethesda (MD): National Heart, Lung, and Blood Institute; 2002 September. Report No.: NIH Publication No. 02–5215. 2002
   Google Scholar
• Kwiterovich PO. A review of lipid-modifying drugs used alone and in combination. Adv Studies Med 2005;5:475–91
   Google Scholar
• Crestor [prescribing information]. Wilmington, DE: AstraZeneca; 2005
   Google Scholar
• Bays H. Statin safety: an overview and assessment of the data – 2005. Am J Cardiol 2006;97:S6–S26
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94: 795–7
   PubMed Web of Science ®Google Scholar
• Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 1991;40(Suppl 1):S53–S58
   PubMedGoogle Scholar
• Myant NB, Mitropoulos KA. Cholesterol 7 alpha-hydroxylase. J Lipid Res 1977;18:135–53
   PubMed Web of Science ®Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779–90
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints 2000;41:708–9
   Google Scholar
• WelChol [prescribing information]. Parsippany (NJ): Daiichi Sankyo, Inc; 2003
   Google Scholar
• Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257–73
   PubMed Web of Science ®Google Scholar
• Anon. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351–64
   Web of Science ®Google Scholar
• Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313–24
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893–900
   PubMed Web of Science ®Google Scholar
• Insull Jr W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971–82
   PubMed Web of Science ®Google Scholar
• Bays H. Ezetimibe. Expert Opin Investig Drugs 2002;11:1587–604
   PubMed Web of Science ®Google Scholar
• Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124–8
   Google Scholar
• Zetia [prescribing information]. North Wales (PA): Merck/ Schering-Plough Pharmaceuticals; 2005
   Google Scholar
• Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363–8
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30
   PubMed Web of Science ®Google Scholar
• FDA. United States Food and Drug Administration, Code of Federal Regulations Title 21, Volume 5, Section 312.32, IND Safety Reports, http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm. 2005
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198–205
   PubMed Web of Science ®Google Scholar
• Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306–10
   PubMedGoogle Scholar